We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
From Apr 2019 to Apr 2024
By Michael Dabaie
GlaxoSmithKline PLC and Vir Biotechnology Inc. said the European Medicines Agency has started a review of VIR-7831 for the early treatment of Covid-19.
The companies said the review is for VIR-7831 for adults and adolescents 12 years and over with Covid-19 who don't require oxygen supplementation and who are at high risk of progressing to severe Covid-19.
GlaxoSmithKline ADRs were up 5% to $38.04 ion morning trading and Vir shares were up 0.3% to $45.69.
The review is being carried out by the EMA's Committee for Human Medicinal Products.
The review will include data from an interim analysis of efficacy and safety data from the Phase 3 COMET-ICE trial. GSK is planning to submit a full marketing authorization application to the EMA which will include the data from the COMET-ICE trial.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 15, 2021 10:42 ET (14:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
